Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Sema4 and BioSymetrics partner on drug discovery in cardiovascular, rare and neurological diseases

Feb. 23, 2022

Chinese researchers divulge 5-HT2AR antagonists and/or melatonin MT1 and/or MT2 receptor agonists

Feb. 22, 2022

Alkem signs license agreement with Harvard for technology to treat vascular disease

Feb. 11, 2022

Bristol Myers Squibb presents new FPR agonists

Feb. 7, 2022

Klotho Therapeutics synthesizes novel compounds for hypertension

Feb. 7, 2022

Praxis Precision Medicines discovers potassium channel subfamily T member 1 inhibitors

Feb. 4, 2022

DDO-02005, a novel potent Kv1.5 potassium channel inhibitor with antiarrhythmic activity

Feb. 1, 2022

OR6A2 is a therapeutic target for atherosclerosis, researchers unveil

Feb. 1, 2022

Cereno advances CS-014 for cardiovascular diseases

Jan. 28, 2022

Therapeutic CAR T cells generated in the body reduce fibrosis in heart disease model in vivo

Jan. 26, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...